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Abstract
Objective To assess the impact of the 2004 extension of the CONSORT
guidelines on the reporting and methodological quality of cluster
randomised trials.
Design Methodological review of 300 randomly sampled cluster
randomised trials. Two reviewers independently abstracted 14 criteria
related to quality of reporting and four methodological criteria specific
to cluster randomised trials. We compared manuscripts published before
CONSORT (2000-4) with those published after CONSORT (2005-8).
We also investigated differences by journal impact factor, type of journal,
and trial setting.
Data sources A validated Medline search strategy.
Eligibility criteria for selecting studies Cluster randomised trials
published in English language journals, 2000-8.
Results There were significant improvements in five of 14 reporting
criteria: identification as cluster randomised; justification for cluster
randomisation; reporting whether outcome assessments were blind;
reporting the number of clusters randomised; and reporting the number
of clusters lost to follow-up. No significant improvements were found in
adherence to methodological criteria. Trials conducted in clinical rather
than non-clinical settings and studies published in medical journals with
higher impact factor or general medical journals were more likely to
adhere to recommended reporting and methodological criteria overall,
but there was no evidence that improvements after publication of the
CONSORT extension for cluster trials were more likely in trials conducted
in clinical settings nor in trials published in either general medical journals
or in higher impact factor journals.
Conclusion The quality of reporting of cluster randomised trials improved
in only a few aspects since the publication of the extension of CONSORT
for cluster randomised trials, and no improvements at all were observed
in essential methodological features. Overall, the adherence to reporting
and methodological guidelines for cluster randomised trials remains
suboptimal, and further efforts are needed to improve both reporting and
methodology.
Introduction
In recent years, increasing attention has been paid to the
importance of good reporting practices as they relate to the
potential utility of a manuscript.1 The CONSORT (consolidated
standards of reporting trials) statement, originally published in
1996 and updated in 2001 and 2010, provides authors and editors
with a checklist for a minimum set of recommendations for
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reporting the trial design, analysis, and results.2Although certain
inadequacies remain common, the quality of reporting of
randomised controlled trials in medical journals seems to be
improving over time.3A recent systematic review indicated that
the CONSORT statement has played an important role in this
progression.4
Unfortunately, reviews of published cluster randomised trials
(see box 1) have repeatedly found important shortcomings in
their methodological conduct and reporting.5-18 For example, a
review of 152 cluster randomised trials published 1997-2000
found that most of them did not adhere to recommendedmethods
for cluster randomised trials.8 To help address this problem, an
extension for the original CONSORT guideline, specifically
addressing the unique methodological features of cluster
randomised trials, was published in 2004.19 In this extension,
the authors altered the recommendations for 15 of 22 items on
the original CONSORT checklist to emphasise the additional
requirements for adequatemethodological conduct and reporting
of cluster randomised trials. Encouragingly, a review of 34
primary care trials published in seven major medical journals
during the two years after the extension found that most trials
properly accounted for clustering in the sample size and in the
analysis.7 Nevertheless, that review still found that cluster
randomised trials often had suboptimal reporting to the extent
that both internal and external validity were uncertain.7 For
example, blinding of participants was not reported clearly in
33% and blinding of outcome assessors was not reported clearly
in 38%. Such factors are included in the CONSORT checklist
for a good reason: lack of blinding can lead to substantially
inflated estimates of effect,20 21 making clear reporting essential
for interpretation. Although blinding of participants is often
impossible in cluster randomised trials, especially in those
evaluating interventions to change behaviour, we believe that
inability to blind trial participants should not be invoked as an
excuse for poor reporting.
Given that cluster trials are increasingly common but carry
unique risks for bias, adequate reporting is evenmore important.
The CONSORT extension for cluster randomised trials might
have had a positive impact on reporting; our group has recently
shown that more reports of cluster randomised trials now
mention the clustered nature of the trial in the title or abstract,
or both.22 We performed a secondary analysis of data originally
abstracted to investigate the unique ethical issues that arise as
a result of randomising groups rather than individuals.23 Using
data from a random sample of published cluster randomised
trials from 2000-8, we examined trends in the reporting quality
of these trials. In addition to investigating whether there was
an improvement in reporting of certain items recommended by
the CONSORT extension, we assessed whether there were
improvements in essential methodological requirements for
cluster randomised trials. To do so, we made a distinction
between reporting in the manuscript (such as presence of a
sample size calculation) and proper methodological conduct
(such as accounting for the intracluster correlation in that
calculation). Finally, we examined whether trends in trial
reporting and methods varied according to characteristics of the
study or journal.
Methods
Search strategy and article selection
We used a previously published electronic search strategy (box
2) to identify reports of cluster randomised trials in health
research, published in English language journals from 2000 to
2008.22 As described in more detail elsewhere,22 23 the search
strategy was derived and validated with an ideal set of cluster
randomised trials identified frommanual examination of a large
sample of health journals, as well as an independent sample of
cluster randomised trials included in previously published
reviews. The sensitivity of the search strategy against the ideal
set of trials, defined as the proportion of cluster randomised
trials that are retrieved by the search, was 90.1%.
Reports identified by the search strategy were sorted in random
order with a computer generated random number, and two
reviewers (MT and CB) screened titles and abstracts of reports
(as well as full text when necessary) to identify cluster
randomised trials that met our eligibility criteria. Both reviewers
initially screened reports to assess agreement in the identification
of eligible trials. After reaching satisfactory agreement (defined
as κ≥0.85), reports were screened independently until the target
sample size of 300 trials was reached (fig 1)⇓. An article was
included if it was clearly the main report of a cluster randomised
trial. We excluded studies identified by the trial authors as
“pilot” or “feasibility” studies, trial protocols, trials randomising
households or dyads of different individuals, short
communications or conference proceedings, trials with further
allocation of individuals within clusters, those using
quasi-randomised designs, and studies that reported only
baseline findings or secondary analyses of trials. We considered
a study as a “secondary analysis” if it was identified as such by
the study authors, referenced the main publication elsewhere,
or presented only secondary outcomes.
Data abstraction
The research team developed and pilot tested the data abstraction
instrument used for the larger project examining ethical issues
in cluster randomised trials. This was then applied to a sample
of 21 cluster randomised trials to calibrate reviewers. Six
reviewers (MT, AMcR, CB, SD, JT, ZS) independently
abstracted these 21 trials. Differences were identified and
resolved by discussion. The rest of the trials were then abstracted
independently by rotating pairs of reviewers. After each set of
20 trials had been abstracted, discrepancies were reviewedwithin
the pair and resolved by consensus. If differences could not be
resolved, one reviewer (MT) was the arbitrator.
Outcomes
Similar to the approach taken in a previous review,8 we
considered criteria relating to both reporting andmethodological
quality of the trials. Reporting quality was assessed on the basis
of the presence or absence of a subset of criteria in the
CONSORT extension to cluster randomised trials;
methodological quality was assessed on the basis of four
methodological requirements specific to the conduct of such
trials. These are related to the criteria described in the
CONSORT extension checklist, but they have been abstracted
to assess appropriateness of trial conduct rather than simply
trial reporting. Table 1⇓ compares the criteria in the CONSORT
checklist and the variables assessed as outcomes in the present
study.
Reporting criteria
Although there are 22 items listed in the CONSORT reporting
checklist for cluster randomised trials, some are difficult to
abstract in a standardised fashion and others can be broken down
into multiple variables. As part of the larger project investigating
ethical issues in cluster randomised trials, we abstracted 14
CONSORT related reporting variables. The choice not to
abstract all CONSORT criteria represented a compromise
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Box 1 Brief description of cluster randomised trials
• Cluster randomised trials differ from classic (individual level) randomised controlled trials in that the unit of randomisation
includes a group (or cluster) of patients—such as a medical practice, hospital, or entire community—rather than an
individual patient
• Cluster randomised trials are often done for pragmatic purposes (such as in public health trials where the intervention
is directed at the whole community) or to avoid contamination of the treatment arm (such as in health services trials
where patients in the intervention group share a healthcare provider)
• Individuals nested within a cluster might bemore similar than individuals from other clusters; this “intracluster correlation”
must be accounted for in the design and analysis
• Failing to account for the intracluster correlation in the calculation of the sample size can lead to an underpowered
trial, and failing to account for it during the analysis can lead to spuriously significant results
• Numerous other challenges separate cluster randomised trials from individual level trials (for example, loss to follow-up
of clusters can substantially reduce power compared with loss of individuals)
Box 2: Medline search strategy to identify cluster randomised trials
1. randomized controlled trial.pt.
2. animals/
3. humans/
4. 2 NOT (2 AND 3)
5. 1 NOT 4
6. cluster$ adj2 randomi$.tw.
7. ((communit$ adj2 intervention$) OR (communit$ adj2 randomi$)).tw.
8. group$ randomi$.tw.
9. 6 OR 7 OR 8
10. intervention?.tw.
11. cluster analysis/
12. health promotion/
13. program evaluation/
14. health education/
15. 10 OR 11 OR 12 OR 13 OR 14
16. 9 OR 15
17. 16 AND 5
between comprehensiveness and feasibility, given the large
sample size involved. For every trial report, we classed each of
the following criteria as “reported” or “not reported”:
• Clear identification of cluster randomised in the title or
abstract of the report
• Explicit provision of a rationale or justification for using
a clustered design (such as avoidance of contamination)
• Reporting of clearly defined primary outcome measures
• Presentation of calculation of sample size
• Identification of who enrolled participants in the trial
(excluding trials with no enrolment of participants—for
example, trials using data from secondary sources only)
• Reporting of the blinding of participants
• Reporting of the blinding of administrators or outcome
assessors, or both
• Presentation of a clearly defined approach to analysis
• Reporting of the number of clusters randomised to each
arm
• Reporting of the number of clusters that withdrew
• Reporting of the number of clusters that were lost to
follow-up
• Reporting of the size of clusters in each arm
• Reporting of the number of individuals lost to follow-up
• Reporting of an estimated intracluster correlation
(excluding trials using a pair matched design or those where
the analysis was at the cluster level).
Methodological criteria
We abstracted four criteria related to the appropriate conduct
of a cluster randomised trial:
• Whether or not the sample size calculation (if reported)
accounted for clustering.24A trial was classified as meeting
the sample size requirement if the sample size calculation
was presented and clearly accounted for clustering (such
as by using the intracluster correlation, coefficient of
variation, or cluster level summary statistics).
• Whether or not the analysis accounted for clustering.24 A
trial was classified as meeting the analysis requirement if
the method of analysis was reported and was clearly
appropriate for the clustered design (such as by adjusting
for the intracluster correlation, using a mixed effects
regression analysis, or using cluster level summary
statistics).
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• Whether any attempt was made beyond simple
(unrestricted) randomisation to attain balance at
baseline—cluster randomised trials have a greater risk of
chance imbalances at baseline compared with trials
randomising individual patients because of the limited
number of clusters that can feasibly be randomised in any
one trial. Restricted randomisation (using stratification,
pair matching, or minimisation) to limit the chance of
baseline imbalances is therefore recommended.19
• As in a previous review,8we abstracted whether the number
of clusters randomised per arm was greater than four as
trials randomising fewer than four clusters per arm might
be severely limited in their statistical power.25 Unlike each
of the variables above, this criterion was not explicitly
recommended in the CONSORT extension for cluster trials.
Study and journal characteristics
We assessed the study setting as well as the type of journal and
its impact factor for each manuscript. To distinguish between
trials conducted in clinical settings or non-clinical settings we
assessed the unit of allocation. We classified the study setting
as “clinical” when the unit of allocation was a healthcare
provider, teams of healthcare providers, or healthcare
organisations (such as a primary care practice or group of
practices, hospital or hospital wards, nursing home) or if the
trial was conducted in a healthcare organisation; the remainder
of the trials (such as those randomising schools or classrooms;
residential areas; worksites; and sports teams, clubs, churches,
or other social groups) were classified as “non-clinical.” We
obtained journal impact factors from journal citation reports
(ISI Web of Science, 2009). When a journal’s ranking was
unavailable, we used the impact ranking of the open access
SMImago journal and country rank database, if available.26 This
ranking is calculated with a similar formula and is strongly
correlated with the journal citation impact factor.27 We used
journal citation reports from ISI Web of Knowledge to identify
general medical journals according to those classified as
“medicine, general and internal.”
Analysis
Results were summarised with frequencies and percentages for
categorical variables and medians and interquartile ranges for
continuous or ordinal variables. For our primary objective of
determiningwhether there has been an improvement in reporting
and methodological quality over time, we compared the
proportions of manuscripts meeting the recommended criteria
published before CONSORT (2000-4) with those published
after CONSORT (2005-6 and 2007-8) using Cochran-Armitage
tests for trend. As seen in figure 2⇓, the number of citations of
the extension increased linearly over this timeframe, and we
therefore chose two cut-off points to account for the expected
gradual dissemination of the guidelines over time. To quantify
the magnitude of change in adherence over time, we calculated
the absolute change in the proportion of trials meeting each
recommendation from before to after CONSORT, together with
95% asymptotic confidence intervals (or exact confidence
intervals in the case of small expected frequencies). We also
created a summary score for the 14 reporting criteria,
representing the proportion of items adhered to in the report.
Differences in the summary score over time were analysed with
one way analysis of variation (ANOVA) with publication year
as a three level categorical variable. For our secondary objective
(to investigate variations in adherence to reporting and
methodological criteria according to study or journal
characteristics) we repeated the above analyses after classifying
trial setting as clinical versus non-clinical and after classifying
journals as higher (above the median) versus lower impact
factors and as general medical journals versus other. All analyses
were carried out with SAS v.9.2 with a level of significance set
at α=0.05.
Results
Table 2 shows characteristics of the 300 randomly selected trials
included in the review⇓. Trials were published in 150 different
journals; 103 (34%) were published in general medical journals.
Journal impact factors ranged from 0.45 to 50; the median
impact factor was 2.9. The median impact factor of the general
medical journals was 9.2.
Table 3⇓ shows the percentage of trials that met each of the
reporting criteria before and after CONSORT, together with the
tests for trend and confidence intervals for absolute change in
adherence. Five of the 14 reporting criteria showed a significant
trend for improvement: reporting on loss of clusters to follow-up
(P=0.01); identification as “cluster randomised” in title or
abstract (P=0.038); providing a justification for the clustered
design (P=0.038); reporting whether or not outcome assessors
had been blinded (P=0.019); and reporting of the number of
clusters randomised (P=0.035). Among these criteria, the
absolute improvement in adherence ranged from 6.6% (95%
confidence interval −1.1% to 14.3%) for reporting of number
of clusters randomised to 13.9% (3.1% to 24.7%) for reporting
whether outcome assessors were blinded. Notably, there was
no improvement in the proportion of trials clearly identifying
a primary outcome, with fewer than half of trials overall meeting
this important criterion; moreover, about half of trials overall
failed to report a sample size calculation and this does not seem
to have improved over time. Based on the summary score, there
was minimal improvement in overall reporting, with papers
from 2000-4 reporting a mean of 60% of criteria, those from
2005-6 reporting 62%, and those from 2007-8 reporting 66%
(P=0.09 for trend).
We found no trend over time in the methodological criteria that
we chose to abstract. Overall, 56% of trials used restricted
randomisation, 70% accounted for clustering in analysis, 60%
of those presenting sample size calculations accounted for
clustering in the design, and 86% allocated more than four
clusters per arm.
Tables 4, 5, and 6 show the results of our secondary analyses,
which examined the role of study and publication characteristics
on improvement in quality of reporting and methodological
conduct before and after the publication of the CONSORT
extension for cluster randomised trials. In particular, table 4
shows that general medical journals performed at a higher
standard overall for nearly every criterion with the exception
of justification for clustering⇓. When considering the change
from before to after CONSORT, the general medical journals
showed significant improvement in only one criterion: reporting
of number of clusters lost to follow-up (absolute improvement
17%, 3% to 31%). No significant improvements in any of the
methodological criteria were observed in trials published in
either the general medical or other journals. Based on the
summary score, trials published in general medical journals
reported a mean of 66.5% of criteria before and amean of 71.6%
of criteria after the CONSORT extension was published
(absolute improvement 5%, −1.7% to 12%), while trials
published in other journals reported a mean of 56% before and
60% after (absolute improvement 4.3%, −1.1% to 9.7%).
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Table 5⇓ shows similar findings: higher impact journals tended
to score better in most reporting and methodological criteria.
Higher impact factor journals showed significant improvements
in two of 14 reporting criteria and in one of four methodological
criteria, while lower impact factor journals improved in two
reporting criteria. Based on the summary score, trials published
in higher impact factor journals reported a mean of 66.0% of
criteria before and a mean of 68.3% of criteria after the
CONSORT extension was published (absolute improvement
2.2%, −3.6% to 8.3%), while trials published in lower impact
factor journals reported a mean of 54.4% before and 59.2% after
(absolute improvement 4.8%, −1.4% to 11.0%).
The results in table 6⇓ follow the same pattern: trials conducted
in clinical settings tended to meet more of the reporting and
methodological criteria than trials conducted in non-clinical
settings. Trials from clinical settings showed significant
improvements in one reporting criterion and onemethodological
criterion, while the trials from non-clinical settings did not show
significant improvements in any of the criteria. Based on the
summary score, trials conducted in clinical settings reported a
mean of 63.3% of criteria before and a mean of 67.8% of criteria
after the CONSORT extension was published (absolute
improvement 4.6%, −1.1% to 10.3%), while trials published in
non-clinical settings reported amean of 55.3% before and 58.2%
after (absolute improvement 2.9%, −3.7% to 9.4%).
Discussion
Statement of principal findings
There have been significant improvements over time in only
five of 14 CONSORT related reporting criteria for cluster
randomised trials. In particular, reporting whether outcome
assessments were blind, as well as the number of clusters
randomised, withdrawn, and lost to follow-up per arm has
considerable implications for assessment of internal validity.28
Although the absolute improvements were small, the trends
represent an important accomplishment because through
improved clarity of reporting, readers canmake better judgments
regarding the risks of bias for any given study.1 While this
progress is welcome, the pace remains slow, and there remains
considerable room for further improvement. The findings from
our review suggest that future updates of the CONSORT
extension for cluster trials should be accompanied by additional
interventions to help investigators and editors improve the
standards of these trials.
Of the five reporting criteria that had a greater than 75%
adherence rate, four can easily be summarised in a well prepared
cluster-patient flow diagram or in a table summarising baseline
data for cluster and individual level variables, or both.Moreover,
of the five criteria that showed significant improvements over
time, two related to flow of clusters-patients (reporting of
numbers of clusters randomised and lost to follow-up).
Therefore, encouraging the use of such flow diagrams (as
recommended by the CONSORT extension) seems to have been
successful in improving reporting of enrolment and losses of
patients and clusters. Even for trials conducted in clinical
settings and published in journals with higher impact factors,
however, there remains a great need for further improvements
in other reporting criteria, possibly through the development of
similar devices within manuscripts that facilitate the
communication of key information. Studies conducted in clinical
rather than non-clinical settings and published in general medical
and other higher impact journals were more likely to meet the
criteria for both reporting and methodological conduct, but the
standards of these studies failed to improve significantly in
many areas after the CONSORT extension was published.More
stringent editorial policies might be required to bring about
substantial improvement. Although journal editorial policies
that promote CONSORT are associated with improved
reporting,29 a recent survey of 165 high impact journals found
that only 3% refer to the extension to cluster trials in the online
instructions for authors.30
Some CONSORT related variables might be poorly reported
because they are deemed unnecessary by investigators or editors.
For example, justification for conducting a cluster level
randomisation might be considered unnecessary in cases when
the intervention itself is at the level of the cluster. In a post hoc
analysis in which we excluded trials with interventions solely
at the cluster level (n=99), however, the proportion reporting a
justification remained low (33%). We agree with the authors of
CONSORT that explicit justification is important because cluster
randomised trials involve unique methodological challenges
that require special attention during the design and analysis.19
For example, the intracluster correlation must be accounted for
in both the sample size calculation and analysis; failure to clearly
report whether this has been done leads to questions regarding
the validity of the findings. Unfortunately, we found no evidence
of significant improvement over time in four keymethodological
criteria. Indeed, the methodological quality of cluster
randomised trial reports after publication of the CONSORT
extension remains disappointingly poor; this is especially true
for trials published in specialty (non-general) medicine journals.
Comparison with literature
Many previous authors have noted problems with the design,
analysis, and reporting of cluster randomised trials. For example,
the reporting of an intracluster correlation represents an
important contribution to the literature, allowing future studies
to plan for adequate power. Only 18% of the 300 manuscripts
that we reviewed, however, reported an intracluster correlation
(or 16% after we excluded trials with a pair matched design or
those with analysis at the cluster level). This is higher than
previous estimates of 4%8 and 8%.5 Our finding that only 31%
of manuscripts provided a clear justification for using a cluster
randomised design also seems positive in light of the previous
finding from a review of 152 cluster randomised trials published
from 1997 to 2000, which found that only 14% justified the use
of a clustered design.8 In contrast, we found that only 50%
reported clearly whether administrators or participants were
blinded, and only 38% reported whether outcome assessors were
blinded, whereas a previous review of 34 cluster randomised
trials in primary care published in 2004 or 2005 found that 67%
and 62% clearly reported whether participants or outcome
assessors were blinded, respectively.7Nevertheless, our findings
indicate that the reporting of blinding of outcome assessment
could be improving over time. This is encouraging as blinding
plays an essential role in any assessment of internal validity or
risk of bias, or both. Intriguingly, reporting of blinding might
be superior in cluster randomised trials than in individually
randomised trials; a recent review of 144 trials from 55 high
impact factor (median 7.67) journals found that only 25%
adequately reported blinding.31
About 40% of the trials in our review that reported a sample
size calculation failed to account for clustering, while 30% failed
to account for clustering in the analysis. Improvement over time
in these crucial aspects was suggested by a previous review that
assessed 18 trials12 published from 1983 to 2003 and was also
observed in an (unpublished) overview of methodological
reviews that assessed the quality of cluster randomised trials
published from 1973 to 2008.32 Still, inappropriate analytical
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methods that inflate the risk of type 1 and type 2 error remain
common in cluster randomised trials in various clinical
specialties.5-8 13-15
We found that only 86% of trials allocated a minimum of four
clusters to each arm of the study. Past reviews of 152 cluster
randomised trials in primary care and 60 trials in public health
found that 91%8 and 92%6 of trials, respectively, met this
criterion, but a review of 75 cluster randomised trials in cancer
care found that only 67% had sufficient numbers of clusters per
arm.5 This might reflect the challenge of recruiting clusters
rather than individuals, but the ability to make valid inferences
regarding intervention effects in studies with few clusters is
severely compromised.When further recruitment is impossible,
investigators should consider other design options.33The reviews
focusing on public health and on cancer trials each found 5%
of studies allocated only one cluster per arm. In our study, 10
trials (3%) had only one cluster per arm. Investigators should
recognise that in trials with only one cluster per arm, the
intervention effect is completely confounded by the cluster
effect.
Low numbers of clusters increase the likelihood of cluster level
differences between study arms. Furthermore, clustering itself
can make it difficult to achieve balance across arms for
individual level variables when only simple randomisation is
used to allocate clusters.34 In our review, 41% of the trials used
simple randomisation rather than an allocation technique more
likely to achieve balance at baseline. Previous reviews found
that trials used simple randomisation rather than stratification
or matching techniques 40%5 to 46%8 of the time. The
CONSORT extension for cluster randomised trials warns against
the risk of baseline imbalance from use of simple
randomisation,19 and, although matching could overcome this
problem, it leads to difficulties in estimating intracluster
correlations and can complicate analyses.10 Although we did
not actually assess for imbalance at baseline, one previous
review found that three of 36 cluster randomised trials published
in the BMJ, Lancet, andNew England Journal of Medicine from
1997 to 2002 had evidence for cluster imbalance, while in 15
the adequacy of balance was deemed unclear.13 This indicates
the need for investigators (and editors) to strongly consider the
value of allocation techniques other than simple randomisation
to achieve baseline balance in cluster randomised trials.35
Strengths and weaknesses of the study
Any study that does not consider the entire population could be
susceptible to selection bias; it is plausible that different
conclusions would be found by looking at a different sample.
We mitigated this risk in our study by abstracting what is (to
our knowledge) the largest ever sample of cluster randomised
trials for a methodological review and the first to use a search
strategy that aimed to produce a sample of cluster trials
representative of all Medline publications. This search strategy
had a sensitivity of 90%, meaning that the random sample used
in this study was representative of most cluster randomised trials
in health research published in Medline from 2000 to 2008. If
the 10% of cluster randomised trials not identified by our search
strategy were systematically different with respect to reporting
or methodological quality, however, this could bias our results.
In particular, as trials that are not clearly identified as “cluster
randomised” in titles and abstracts of reports might also be less
likely to adhere to recommended methodological and reporting
standards, our results might overestimate the proportion of trials
adhering to these standards. Although the sample was large
relative to previous methodological reviews, it was determined
by the objectives of the larger study focusing on ethical issues
in cluster trials and we were therefore not specifically powered
to detect small improvements in reporting. In particular,
assuming the most conservative estimate of adherence of 50%
before CONSORT, improvements to 60% and 70% adherence
after CONSORT (2005-6 and 2007-8, respectively) would have
been required to allow 80% probability of detecting a significant
trend. Naturally, similar limitations extend to the secondary
analyses involving subgroups defined by study or journal
characteristics.
We used a unique summary score for adherence to 14
CONSORT based reporting variables relevant to cluster
randomised trials. We believe this is helpful because it provides
a sense of overall quality of reporting, but we do not intend to
suggest by providing this score that each criterion is of equal
importance. Although similar summary scores have been used
before in other reviews of reporting standards,4 readers should
note this caveat in addition to the other known limitations of
quality scales.36 Furthermore, we acknowledge the risk of
spurious findings associated withmultiple testing in our analyses
and recommend that significant results be interpreted cautiously.
Finally, there are numerous criteria that we did not abstract in
this review that could have important implications with respect
to internal or external validity, such as baseline imbalances for
clusters and participants, as well as risks of identification and
recruitment bias. The extension to CONSORT for cluster
randomised trials might have resulted in improvements in
reporting for criteria other than those that we abstracted. It is
also likely that the extension had a greater impact in journals
that actively endorsed (and explicitly enforced) the guideline.
Unfortunately, we were unable to evaluate this because of the
difficulty in determining when CONSORT extensions were
endorsed by each journal or how they were enforced.
Implications
Although we observed some improvement over time related to
the publication of the CONSORT extension, we found an
ongoing need for attention to the proper reporting and
methodological conduct in cluster randomised trials. As the
extension to CONSORT for cluster randomised trials was
published in a general medical journal, investigators conducting
trials in non-clinical settings or publishing in other journal
categories (such as public health journals) might not have been
aware of the extension, thus leading to the relatively poorer
performance observed in this group. Themost recent CONSORT
guidelines for individual level randomised controlled trials were
published in a wide range of clinical journals. Future updates
for the CONSORT extension to cluster trials should consider a
similar (or even broader) approach.
The slow uptake of guidelines into practice is a problem that
extends beyond the clinic and into the realm of publication. It
seems likely that more than the publication of the CONSORT
guideline is required to assist editors and investigators in proper
conduct and reporting of cluster randomised trials. Improved
collaboration with guideline developers and new tools to support
the efforts of editors and investigators should be made available
to support the publication of more transparent and higher quality
cluster randomised trial manuscripts.
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Tables
Table 1| Comparison of recommendations in extension to CONSORT for cluster randomised trials and variables abstracted for present
study
Description of variable abstracted for this review
Criterion included in present
study?CONSORT criterion
Clearly identified as cluster randomised trial in title or
abstract
Yes (reporting)1) Specify that allocation was based on clusters
Justification provided for using clustered designYes (reporting)2) Rationale for using cluster design
—No3) Eligibility criteria for participants and clusters
—No5) Interventions intended for individual level, cluster level, or both
—No5) Specific objectives for individual level, cluster level, or both
Primary outcome identified clearlyYes (reporting)6) Report outcome measures for individual level, cluster level, or both
Sample size calculation presentedYes (reporting)7) How total sample size was determined including method of
calculation, No of clusters, cluster size, coefficient of intracluster
correlation
Accounted for clustering in sample sizeYes (methodology)
Used stratification/matching/minimisationYes (methodology)8) Method used to generate random allocation sequence
—No9) Method used to implement random allocation sequence
Identified who enrolled patientsYes (reporting)10) Who generated allocation sequence and enrolled and assigned
participants
Reported on blinding of outcome assessors; reported
on blinding of participants/administrators
Yes (reporting)11) Whether participants, those administering interventions, and those
assessing outcomes were blinded to group assignment
Reported methods of analysisYes (reporting)12) Statistical methods used to compare groups for primary outcome(s)
indicating how clustering was taken into account
Accounted for clustering in analysisYes (methodology)
Reported No of clusters randomised; reported No of
individuals lost to follow-up; reported No of clusters lost
to follow-up; reported No of clusters withdrew; reported
size of clusters in each arm
Yes (reporting)13) Flow of clusters and individual participants through each stage
—No14) Dates defining periods of recruitment and follow up
—No15) Baseline information for each group for individual and cluster levels
Similar to 13 aboveYes (reporting)16) No of clusters and participants in each group included in each
analysis and whether analysis was by intention to treat
Allocated minimum of four clusters per armYes (methodology)
Reported intracluster correlationYes (reporting)17) For each outcome, summary of results for each group for individual
or cluster level, and coefficient of intracluster correlation.
—No18) Address multiplicity by reporting any other analyses performed
—No19) All important adverse events or side effects in each intervention
group
—No20) Interpretation of results (internal validity)
—No21) Generalisability (external validity)
—No22) Interpretation in context of current evidence
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Table 2| Characteristics of 300 cluster randomised trials included in review of studies for compliance with CONSORT extension. Figures
are numbers (percentage) of trials unless stated otherwise
DataCharacteristic
Publication year:
139 (46)2000-4
93 (31)2005-6
68 (23)2007-8
Journal impact factor (n=294):
2.9 (2.1-5.1)Median (IQR)
0.45-50.0Range
Country of study recruitment:
114 (38)USA
50 (17)UK or Ireland
16 (5)Canada
16 (5)Australia or New Zealand
104 (35)Other
Clinical setting (unit of allocation):
81 (27)Medical practices or clinics
41 (14)Individual health professionals
25 (8)Hospitals, hospital units, hospital wards
16 (5)Nursing homes or wards
6 (2)Other (such as postal codes of family practices)
Non-clinical setting (unit of allocation):
66 (22)Schools or classrooms
39 (13)Residential areas (such as villages, districts, housing units)
16 (5)Worksites
10 (3)Sports teams, clubs, churches, other social groups
No of clusters randomised (n=285):
21.0 (12-52)Median (IQR)
2-605Range
Average cluster size (n=271):
33.9 (12.5-88.5)Median (IQR)
1.7-122 855Range
No of participants per arm (n=290):
329 (143-866)Median (IQR)
20-614 275Range
IQR=interquartile range.
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Table 3| Adherence (number (percentage)) to standard criteria for reporting and methodology for cluster randomised trials, overall and
before and after publication of CONSORT extension for cluster randomised trials
Absolute change in %
adherence (before to after)
(95% CI)
P value for
trend
After (2007-8,
n=68)
After (2005-6,
n=93)
Before (2000-4,
n=139)Overall (n=300)
Criteria related to quality of reporting
11.0 (−0.3 to 22.2)0.03839 (57)47 (50.5)59 (43)145 (48)Clearly identified as clustered in title
or abstract
8.8 (−1.6 to 19.2)0.03828 (41)29 (31.2)37 (27)94 (31)Justification provided for using
cluster design
13.9 (3.1 to 24.7)0.01931 (46)40 (43.0)42 (30)113 (38)Reported on blinding of outcome
assessors
−2.7 (−14.1 to 8.6)0.29229 (43)50 (53.8)72 (52)151 (50)Reported on blinding of
participants/administrators
4.5 (−6.9 to 15.8)0.28436 (53)43 (46.2)62 (45)141 (47)Primary outcome identified clearly
−1.4 (−12.7 to 9.9)0.48343 (63)44 (47.3)77 (55)164 (55)Sample size calculation presented
−3.6 (−16.4 to 9.2)0.67434 (57)41 (55.4)59 (60)134 (58)Identified who enrolled participants*
6.6 (−1.1 to 14.3)0.03564 (94)81 (87.1)116 (84)261 (87)Reported No of clusters randomised
13.3 (3.9 to 22.6)0.01058 (85)78 (83.9)99 (71)235 (78)Reported No of clusters lost to
follow-up
4.8 (−3.3 to 12.9)0.07863 (93)78 (83.9)115 (83)256 (85)Reported No of clusters that
withdrew
5.9 (−1.7 to 13.5)0.08163 (93)82 (88.2)117 (84)262 (87)Reported size of clusters in each
arm
−4.5 (−14.1 to 5.1)0.86054 (79)65 (69.9)109 (78)228 (76)Reported No of individuals lost to
follow-up
2.9 (−2.7 to 8.6)0.45664 (94)89 (95.7)128 (92)281 (94)Reported methods of analysis
−10.2 (−20.3 to 0)0.32310 (18)4 (6.2)21 (22)35 (16)Reported intracluster correlation†
3.5 (−0.8 to 7.8)0.09266.1 (16.9)61.5 (19.9)59.9 (19.6)61.8 (19.2)Mean (SD) summary score
Criteria relating to methodological quality
7.2 (−4.1 to 18.5)0.27240 (59)55 (59.1)72 (52)167 (56)Used restricted randomisation
0.4 (−7.8 to 8.6)0.86757 (86)76 (85.4)111 (85)244 (86)Allocated minimum of four clusters
per arm‡
−9.9 (−24.8 to 4.9)0.66228 (65)21 (47.7)51 (66)100 (61)Accounted for clustering in sample
size§
−4.2 (−14.6 to 6.2)0.47446 (68)63 (67.7)100 (72)209 (70)Accounted for clustering in analysis
*Excludes 67 trials with no participant enrolment.
†Excludes 84 trials with pair matched designs or primary analysis at cluster level.
‡Excludes 15 studies with unclear number of clusters.
§Excludes 136 trials with no sample size calculation presented.
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Table 4| Change in adherence (number (percentage)) to standard criteria for reporting and methodology for cluster randomised trials by
journal type, before and after publication of CONSORT extension for cluster randomised trials
Other journalsGeneral medical journals
Absolute change in
adherence (before to
after) (95% CI)
After (2005-8,
n=113)
Before (2000-4,
n=84)
Absolute change in
adherence (before to
after) (95% CI)
After (2005-8,
n=48)
Before (2000-4,
n=55)
Criteria related to quality of reporting
11.2 (−2.6 to 25.0)53 (47)30 (36)16.0 (−2.6 to 34.6)33 (69)29 (53)Clearly identified as clustered
in title or abstract
7.7 (−5.4 to 20.8)41 (36)24 (29)9.7 (−7.7 to 27.1)16 (33)13 (24)Justification provided for using
cluster design
15.1 (2.3 to 27.9)44 (39)20 (24)16.3 (−2.8 to 35.3)27 (56)22 (40)Reported on blinding of
outcome assessors
−1.9 (−15.9 to 12.2)49 (43)38 (45)0.7 (−18.1 to 19.5)30 (63)34 (62)Reported on blinding of
participants/administrators
5.3 (−8.3 to 18.9)45 (40)29 (35)10.8 (−7.4 to 29.1)34 (71)33 (60)Primary outcome identified
clearly
−1.9 (−16.0 to 12.2)53 (47)41 (49)5.4 (−12.6 to 23.4)34 (71)36 (66)Sample size calculation
presented
1.0 (−14.8 to 16.8)51 (53)33 (52)−9.4 (−30.6 to 11.7)24 (65)26 (74)Identified who enrolled
participants*
7.2 (−2.7 to 17.2)101 (89)69 (82)6.2 (−6.0 to 18.4)44 (93)47 (86)Reported No of clusters
randomised
12.4 (0.2 to 24.6)92 (81)58 (69)17.1 (3.2 to 31.0)44 (93)41 (75)Reported No of clusters lost to
follow-up
4.9 (−5.7 to 15.5)97 (86)68 (81)6.2 (−6.0 to 18.4)44 (93)47 (86)Reported No of clusters that
withdrew
7.2 (−2.7 to 17.2)101 (89)69 (82)4.4 (−7.4 to 16.2)44 (93)48 (87)Reported size of clusters in
each arm
−2.1 (−14.7 to 10.4)81 (72)62 (74)−6.3 (−21.2 to 8.5)38 (79)47 (86)Reported No of individuals lost
to follow-up
2.1 (−5.3 to 9.5)106 (94)77 (92)5.2 (−2.8 to 13.2)47 (98)51 (93)Reported methods of analysis
−6.9 (−23.0 to 9.5)9 (11)11 (18)−16.0 (−38.7 to 7.7)5 (14)10 (30)Reported intracluster
correlation†
4.3 (−1.1 to 9.7)60.0 (18.6)55.7 (19.5)5.1 (−1.7 to 12.0)71.6 (16.7)66.5 (18.1)Mean (SD) summary score
Criteria relating to methodological quality
12.9 (−1.1 to 26.9)63 (56)36 (43)1.2 (−17.1 to 19.5)32 (67)36 (66)Used restricted randomisation
−0.7 (−11.7 to 10.3)89 (82)64 (83)4.9 (−6.1 to 16.0)44 (94)47 (89)Allocated minimum of four
clusters per arm‡
−2.9 (−14.9 to 9.1)25 (22)21 (25)−4.6 (−23.9 to 14.8)24 (50)30 (55)Accounted for clustering in
sample size§
−5.0 (−18.7 to 8.7)67 (59)54 (64)3.9 (−9.7 to 17.4)42 (88)46 (84)Accounted for clustering in
analysis
*Excludes 67 trials with no participant enrolment.
†Excludes 84 trials with pair matched designs or primary analysis at cluster level.
‡Excludes 15 studies with unclear number of clusters.
§Excludes 136 trials with no sample size calculation presented.
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Table 5| Change in adherence (number (percentage)) to standard criteria for reporting and methodology for cluster randomised trials by
journal impact factor*, before and after publication of CONSORT extension for cluster randomised trials
Lower impact factor journalsHigher impact factor journals
Absolute change in
adherence (before to
after) (95% CI)
After (2005-8,
n=82)
Before (2000-4,
n=63)
Absolute change in
adherence (before to
after) (95% CI)
After (2005-8,
n=78)
Before (2000-4,
n=71)
Criteria related to quality of reporting
15.0 (−0.7 to 30.6)37 (45)19 (30)6.5 (−9.3 to 22.2)49 (63)40 (56)Clearly identified as clustered
in title or abstract
2.3 (−12.5 to 17.0)24 (29)17 (27)17.0 (2.0 to 31.9)33 (42)18 (25)Justification provided for using
cluster design
4.4 (−10.7 to 19.5)27 (33)18 (29)21.3 (5.7 to 36.9)43 (55)24 (34)Reported on blinding of
outcome assessors
2.4 (−14.0 to 18.8)41 (50)30 (48)−7.6 (−23.6 to 8.4)38 (49)40 (56)Reported on blinding of
participants/administrators
6.1 (−9.5 to 21.6)31 (38)20 (32)5.2 (−10.6 to 21.0)48 (62)40 (56)Primary outcome identified
clearly
−8.1 (−24.5 to 8.2)35 (43)32 (51)3.3 (−12.0 to 18.6)52 (67)45 (63)Sample size calculation
presented
−2.1 (−21.1 to 17.0)38 (55)24 (57)−4.5 (−22.3 to 13.3)37 (58)33 (62)Identified who enrolled
participants†
14.1 (1.7 to 26.4)74 (90)48 (76)−1.8 (−11.1 to 7.5)70 (90)65 (92)Reported No of clusters
randomised
19.4 (5.0 to 33.9)68 (83)40 (64)7.0 (−5.2 to 19.3)67 (86)56 (79)Reported No of clusters lost to
follow-up
9.2 (−3.8 to 22.2)70 (85)48 (76)−0.4 (−10.1 to 9.3)70 (90)64 (90)Reported No of clusters that
withdrew
11.3 (−1.1 to 23.5)73 (89)49 (78)0.9 (−8.5 to 10.3)71 (91)64 (90)Reported size of clusters in
each arm
−2.3 (−17.0 to 12.5)58 (71)46 (73)−4.9 (−17.5 to 7.8)61 (78)59 (83)Reported No of individuals lost
to follow-up
2.2 (−7.0 to 11.4)76 (93)57 (91)5.8 (−0.7 to 12.2)77 (99)66 (93)Reported methods of analysis
−3.6 (−23.0 to 16.0)8 (13)7 (17)−17.7 (−35.6 to 1.3)6 (10)14 (28)Reported intracluster
correlation‡
4.8 (−1.4 to 11.0)59.2 (18.3)54.4 (19.1)2.2 (−3.6 to 8.3)68.3 (18.0)66.0 (18.7)Mean (SD) summary score
Criteria relating to methodological quality
8.6 (−7.6 to 24.8)50 (61)33 (52)5.6 (−10.4 to 21.6)45 (8)37 (52)Used restricted randomisation
−8.2 (−21.2 to 4.7)62 (78)48 (86)11.7 (2.0 to 21.3)71 (96)59 (84)Allocated minimum of four
clusters per arm§
−19.6 (−43.1 to 3.8)15 (43)20 (63)−3.5 (−22.2 to 15.2)34 (65)31 (69)Accounted for clustering in
sample size¶
−6.7 (−22.9 to 9.5)44 (54)38 (60)1.6 (−10.6 to 13.9)65 (83)58 (82)Accounted for clustering in
analysis
*Excludes six trials with no impact factor.
†Excludes 67 trials with no participant enrolment.
‡Excludes 84 trials with pair matched designs or primary analysis at cluster level.
§Excludes 15 studies with unclear number of clusters.
¶Excludes 136 trials with no sample size calculation presented.
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Table 6| Change in adherence (number (percentage)) to standard criteria for reporting and methodology for cluster randomised trials by
trial setting, before and after publication of CONSORT extension for cluster randomised trials
Non-clinical settingsClinical settings
Absolute change in
adherence (before to
after) (95% CI)
After (2005-8,
n=73)
Before (2000-4,
n=58)
Absolute change in
adherence (before to
after) (95% CI)
After (2005-8,
n=88)
Before (2000-4,
n=81)
Criteria related to quality of reporting
12.8 (−3.7 to 29.3)32 (44)18 (31)10.8 (−4.2 to 25.7)54 (61)41 (51)Clearly identified as clustered
in title or abstract
10.5 (−4.8 to 25.7)24 (33)13 (22)7.9 (−6.3 to 22.1)33 (38)24 (30)Justification provided for using
cluster design
14.6 (−0.9 to 30.0)27 (37)13 (22)14.2 (−0.6 to 29.0)44 (50)29 (36)Reported on blinding of
outcome assessors
−0.9 (−17.6 to 15.8)27 (37)22 (38)−2.6 (−17.4 to 12.1)52 (59)50 (62)Reported on blinding of
participants/administrators
−3.0 (−19.9 to 13.9)28 (38)24 (41)11.0 (−3.9 to 26.0)51 (58)38 (47)Primary outcome identified
clearly
7.0 (−9.5 to 23.5)29 (40)19 (33)−5.7 (−19.6 to 8.3)58 (66)58 (72)Sample size calculation
presented
−6.4 (−24.7 to 11.9)29 (45)26 (51)−2.1 (−19.3 to 15.1)46 (67)33 (69)Identified who enrolled
participants*
6.9 (−3.7 to 17.5)68 (93)50 (86)6.0 (−4.9 to 16.9)77 (88)66 (82)Reported No of clusters
randomised
6.0 (−7.7 to 19.7)61 (84)45 (78)18.6 (5.9 to 31.2)75 (85)54 (67)Reported No of clusters lost to
follow-up
4.2 (−7.0 to 15.4)66 (90)50 (86)5.0 (−6.4 to 16.4)75 (85)65 (80)Reported No of clusters that
withdrew
7.0 (−6.1 to 20.1)63 (86)46 (79)5.5 (−3.4 to 14.4)82 (93)71 (88)Reported size of clusters in
each arm
−7.7 (−23.8 to 8.4)46 (63)41 (71)−1.0 (−12.2 to 10.2)73 (83)68 (84)Reported No of individuals lost
to follow-up
0.7 (−5.3 to 6.7)71 (97)56 (97)4.3 (−4.3 to 12.9)82 (93)72 (88.9)Reported methods of analysis
−18.5 (−39.1 to 3.7)2 (4)8 (23)−5.1 (−21.8 to 11.9)12 (16)13 (21)Reported intracluster
correlation†
2.9 (−3.7 to 9.4)58.2 (18.7)55.3 (18.8)4.6 (−1.1 to 10.3)67.8 (17.7)63.3 (19.7)Mean (SD) summary score
Criteria relating to methodological quality
−7.9 (−25.0 to 9.2)37 (51)34 (59)19.0 (4.3 to 33.7)58 (66)38 (47)Used restricted randomisation
−2.6 (−14.7 to 9.6)61 (85)48 (87)2.8 (−8.3 to 13.8)72 (87)63 (84)Allocated minimum of four
clusters per arm
−11.6 (−38.2 to 14.9)18 (62)14 (74)−10.3 (−28.2 to 7.5)31 (54)37 (64)Accounted for clustering in
sample size‡
−6.6 (-23.3 to 10.0)43 (59)38 (66)−1.5 (−14.5 to 11.4)66 (75)62 (77)Accounted for clustering in
analysis
*Excludes 67 trials with no participant enrolment.
†Excludes 84 trials with pair matched designs or primary analysis at cluster level.
‡Excludes 136 trials with no sample size calculation presented.
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Figures
Fig 1 Identification of sample of 300 cluster randomised trials
Fig 2 Number of citations (assessed with SCOPUS) of CONSORT extension for cluster randomised trials by year of
publication
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